A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement | MicrobiomeTrials← Back to trialsNCT07359820
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-04Est. Completion: 2027-09
Enrollment target: 30 participants Locations- Mayo Clinic, Phoenix, Arizona, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
- Institut Bergonie, Bordeaux, France
- Centre Georges François Leclerc, Dijon, France
- Centre Leon Berard, Lyon, France
- Gustave Roussy Cancer Campus, Paris, France
- Seoul National University Hospital, Seoul, South Korea
- Samsung Medical Center, Seoul, South Korea
- START Barcelona-Hospital HM Nou Delfos, Barcelona, Spain
- Hospital Universitario Fundación Jiménez Díaz- START MADRID, Madrid, Spain
- Hospital Universitario HM Sanchinarro-START MADRID-CIOCC, Madrid, Spain
- University College Hospital (NIHR UCLH Clinical Research Facility), London, United Kingdom
Other microbiome trials you might be interested in
Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and …
La Jolla, United StatesEst. completion Dec 2026
Resectable Intrahepatic Cholangiocarcinoma
This phase II trial tests the safety and effectiveness of preoperative immunotherapy with durvalumab and chemotherapy wi…
Chicago, United StatesEst. completion Dec 10, 2030
Sarah Cannon Research Institute UK, London, United KingdomThe Christie NHS Foundation, Manchester, United Kingdom